If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off
Executive Summary
At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.
You may also be interested in...
Despite Hot Sales, US CBD Market’s Image Problem Cools Growth, Survey Suggests
US CBD consumers say scams and quality control are greatest concerns, and newer users are most concerned, according to a survey of 780 participants by Bigeye. Results also shed light on factors that could be keeping consumers from trying the products.
Lawful Use Of Cannabidiols In Supplements ‘Different Than The Rest’ Of US FDA Regulations?
CFSAN regulatory affairs chief Douglas Stearn says a regulatory pathway wouldn’t be an open door for CBD-containing food and supplements due to concerns about the ingredients’ safety. Legislation from Congress might "do something with CBD that’s different than the rest of the Food, Drug and Cosmetic Act," he says.
Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work
Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.